Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary β-trace protein

Donadio, Carlo

doi:10.1152/ajprenal.00507.2009

Cited by 49 publications

(49 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Urinary excretion of BTP has, thus, been used as a marker of renal dysfunction in animal models (39) and human studies (37,38,40,41). In a rat model experiment, a genetic model of spontaneous noninsulin-dependent diabetes mellitus accompanied by kidney dysfunction was used (39).…”

Section: Btp As a Urinary Biomarker Of Renal Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

β-Trace Protein

Orenes‐Piñero

Manzano‐Fernández

López‐Cuenca

et al. 2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Summary b-trace protein, also known as Lipocalin type prostaglandin D synthase, is a low-molecular mass glycoprotein (between 23,000 and 29,000 Da depending on the degree of glycosylation) that converts prostaglandin H2 into prostaglandin D2. b-trace protein was initially isolated from cerebrospinal fluid and served as a marker of cerebrospinal fluid leakage; however, its cDNA and gene have been isolated in numerous human body tissues, including central nervous system, retina, melanocytes, heart, and male genital organs. In recent years, b-trace protein has emerged as a promising novel endogenous marker of GFR, representing a more sensitive marker for mild kidney dysfunction than serum creatinine. In this regard, b-trace protein has been proposed as an alternative marker to Cystatin C for measuring kidney function. Beyond its role for estimating renal function, b-trace protein is also emerging as a novel biomarker in cardiovascular risk. It has been associated with several cardiovascular disorders, playing a potential role for prognostic stratification in patients with acutely decompensated heart failure and acute coronary syndromes and being advocated as a novel marker for cardiovascular risk prediction.

show abstract

Section: Btp As a Urinary Biomarker Of Renal Dysfunctionmentioning

confidence: 99%

“…Subsequently, two different studies with patients suffering from CKD showed that BTP was a useful marker for the early detection of renal tubular damage and that a BTP urine-based test can predict a slight GFR impairment in CKD patients (40,41).…”

Section: Btp As a Urinary Biomarker Of Renal Dysfunctionmentioning

confidence: 99%

β-Trace Protein

Orenes‐Piñero

Manzano‐Fernández

López‐Cuenca

et al. 2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…BTP, also known as prostaglandin D2 synthase (PGDS), is a glycoprotein with a molecular mass of 23-29 kDa. With decreasing renal function, BTP plasma levels rise [13, 14] and virtually all BTP appears to be freely filtered through the glomerulus – whether this is followed by tubular reabsorption and degradation or not requires further study [12, 15]. Different BTP-based equations were proposed to translate plasma BTP levels to estimated GFR in different non-dialysis populations [16-18] and, more recently, in dialysis patients (i.e.…”

Section: Introductionmentioning

confidence: 99%

Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time

Craenenbroeck¹,

Bragfors-Helin²,

Qureshi³

et al. 2017

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Beta-trace protein (BTP) is a low-molecular-weight molecule, which may be used to assess residual renal function (RRF) in dialysis patients. Here we evaluated the influence of hemodialysis (HD) and hemodiafiltration (HDF) on plasma BTP, and analyzed the inter- and intra-individual variability of plasma BTP over time in HD and peritoneal dialysis (PD) patients. Methods: In 12 prevalent HD patients, the effect of a single session of low-flux HD, high-flux HD and HDF on plasma BTP was studied. Blood samples were taken at baseline, after 120 and 240 minutes, and at the start of the next dialysis session. In 13 HD patients and 10 PD patients, inter- and intra-individual variability over three months was studied (monthly and weekly, respectively). Plasma BTP was measured using a nephelometric method. Results: No significant decrease in plasma BTP was seen following a session of low-flux HD. Both high-flux HD and HDF resulted in a significant decrease immediately after dialysis (22% and 61% median decrease, respectively). A significant reduction of the molecule persisted only in HDF and a significant decrease (-15%) was still found immediately before the start of the next dialysis session. In both HD and PD patients, the reproducibility over time was excellent with intra-class correlation coefficient of 0.96 (0.93-0.99) and 0.92 (0.86-0.99) respectively. In a small cohort of PD patients, fair agreement existed between mGFR (average of renal urea and creatinine clearance from a 24 hours urine collection) and the BTP-based GFR estimation. Conclusion: BTP is a stable marker and a promising tool for RRF estimations in PD and HD patients. In patients receiving HDF, plasma levels of BTP should be interpreted with caution.

show abstract

“…Moreover, b2M is known to correlate with GFR impairment in renal dysfunction [19]. The increase of b2M in CHF patients, in addition to its association with the severity of heart disease and renal impairment, suggests a new role for b2M as biomarker of heart failure progression and prognosis.…”

Section: Discussionmentioning

confidence: 99%

β2-Microglobulin and TIMP1 Are Linked Together in Cardiorenal Remodeling and Failure

Vianello

Caponi²,

Galetta

et al. 2014

Cardiorenal Med

View full text Add to dashboard Cite

Background/Aims: The cardiorenal syndrome is a complication in patients hospitalized with chronic heart failure (CHF). The β₂-microglobulin (b2M) level is an index of decreased glomerular filtration rate (GFR), tissue turnover and inflammation. It is an emerging new predictive marker of cardiovascular events and mortality, but its role as a biomarker of cardiorenal remodeling and failure is still unknown. TIMP1, an endogenous tissue inhibitor of activated matrix metalloproteinases, is a biomarker of heart remodeling and failure. We aimed to evaluate the circulating profile of b2M and TIMP1 in CHF patients, in sedentary controls with no tissue remodeling and in veteran athletes with physiological cardiorenal remodeling and athlete's heart (AH). Methods: We investigated the plasma levels of b2M and TIMP1 in 24 subjects with CHF without primitive renal disease, in 25 sedentary controls and in 30 veteran marathoners with AH over 50 years. Results: The b2M and TIMP1 levels were higher in CHF patients, and there was a correlation between them (r = 0.5287, p < 0.0095). The b2M level correlated with the severity of cardiorenal impairment: with proBNP (r = 0.66, p > 0.0007), percent ejection fraction (r = -0.56, p = 0.0162) and GFR (r = 0.83, p < 0.0001). b2M was also correlated with TIMP1 in AH subjects (r = 0.7548, p < 0.0001) but not in controls. This correlation was independent from GFR in both CHF patients and sedentary controls. Conclusions: In CHF patients, the plasma levels of b2M and TIMP1 were linked together and correlated with the severity of cardiorenal failure. Moreover, a strong correlation between b2M and TIMP1 characterized cardiovascular remodeling not only in CHF patients but also in AH subjects. These findings suggest that clinicians should use b2M and TIMP1 as associated biomarkers of cardiorenal remodeling and failure. © 2014 S. Karger AG, Basel

show abstract

Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary β-trace protein

Abstract: Donadio C. Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary ␤-trace protein.

Cited by 49 publications

References 66 publications

β-Trace Protein

β-Trace Protein

Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time

β2-Microglobulin and TIMP1 Are Linked Together in Cardiorenal Remodeling and Failure

Contact Info

Product

Resources

About